ARCHIVES

Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval

This article is from The Cancer Letter archive.

Vol. 35 No. 8 | August 31, 2012

Download PDF Visit The Full Archive

Related Articles

Congressional Committee, SEC Probe ImClone’s Statements To Shareholders.

January 25, 2002

DRCCA Board, ACCI Agree On New Core Grant Guidelines

February 6, 1981

NCI Developing Plan To Replace Research Contracts At Academic Institutions With “Program Grants”

February 22, 1974

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

December 31, 2010

IARC Publishes Fourth Edition of European Code Against Cancer

October 17, 2014

Firm’s Information System Embedded In iKnowMed For Treatment Outcomes.

June 29, 2001